Larry Ellison, Executive Chair and CTO of Oracle, has cancelled his 10b5-1 stock sale plan. No Oracle shares were sold under this plan, and Ellison has no other intentions to sell his Oracle stock. This move signals stability in his holdings and may reassure investors about his confidence in the company. Oracle continues to focus on its cloud and technology offerings as it moves forward.
Bloom Energy shares fell even after Oracle named it the primary power source for a large AI campus, reflecting concerns over the stock's high valuation and market volatility. The company’s shares have surged 142.5% year-to-date, but trade at very hig...
Shares of CoreWeave dropped 16% and its bond yields surged as investors grew concerned about heavy borrowing by tech firms for AI projects. The yield on CoreWeave's 2032 bond hit nearly 15%, signaling increased risk perception. Other tech companies l...
Mizuho reaffirmed its $320 price target and 'Outperform' rating for Oracle stock, highlighting a potential 123.46% upside from the current $143.20 price. The firm remains positive despite regulatory and infrastructure challenges with Oracle's Project...
CoreWeave's stock fell 10% following a spike in its unsecured bond yields to 15%, signaling increased borrowing costs and credit risk concerns. The company finances its AI chip capacity largely through debt secured by the chips and customer contracts...
Oracle Health, a provider of cloud-based health record systems, suffered a data breach compromising personal and medical information, including names, social security numbers, medical records, and payment details. Multiple hospitals across the U.S. w...
